The forecasting role and forecasting tools as part of a corporate business function, or as part of a commercial consulting project in Pharma, Biotech and Medical Device organisations, continue to evolve. Erik Holzinger (groupH) together with Ben Collins (Boehringer Ingelheim) hosted a round-table discussion during this year’s annual EphMRA 2018 Conference in Basel, during June 26 – 28, to open up a number of key topics to a wider audience, share views and come to a consensus on current best practice.
The group consisted of some very experienced individuals from a broad range of pharma companies and business functions, as well as several people from the agency side, providing for diverse backgrounds and insights into what one individual named “…a very big subject”.
The discussion focussed on four key areas:
- Organising the forecasting process across the Pharma organisation – assumption, communication, and consensus
- How to communicate strategic forecasts and illustrate uncertainties to senior management – does Monte Carlo simulation have a role here?
- Required granularity and scope in forecasting strategic pipeline and in-licensing assets: US + RoW?
- Insights into the application of Behavioural Economics to the forecasting process
View a summary of the discussion with key quotes here
Read the handout which set the scene for these four topics here
EphMRA is planning a Forecasting Roundtable No. 2 at our 2019 meeting in Warsaw. Please send any comments you might have on this year’s roundtable and potential ideas for topics to be discussed at future round tables to firstname.lastname@example.org. We want to hear from you!